UroGen Pharma Ltd
For the period ended Dec 31, 2023. Filed Mar 14, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 14, 2024
URGN$26.31+6.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Financial Statements and Supplementary Data
Item 8. Financial Statements and Supplementary Data
UroGen Pharma Ltd.
Index to financial statements
| Pages | |
|---|---|
| Report of Independent Registered Public Accounting Firm (PCAOB ID 238) | 75 |
| Consolidated Balance Sheets | 76 |
| Consolidated Statements of Operations and Comprehensive Loss | 77 |
| Consolidated Statements of Shareholders’ Deficit | 78 |
| Consolidated Statements of Cash Flows | 79 |
| Notes to Consolidated Financial Statements | 80 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.